Leiser, D., Medová, M., Mikami, K., Nisa, L., Stroka, D., Blaukat, A., . . . Zimmer, Y. (2015). KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET‐expressing tumor cells. Mol Oncol.

Leiser, Dominic, Michaela Medová, Kei Mikami, Lluís Nisa, Deborah Stroka, Andree Blaukat, Friedhelm Bladt, Daniel M. Aebersold, und Yitzhak Zimmer. "KRAS and HRAS Mutations Confer Resistance to MET Targeting in Preclinical Models of MET‐expressing Tumor Cells." Mol Oncol 2015.

Leiser, Dominic, et al. "KRAS and HRAS Mutations Confer Resistance to MET Targeting in Preclinical Models of MET‐expressing Tumor Cells." Mol Oncol 2015.